Retrospectively Analysis Of The Relationship Between XRCC1 And GSTP1 Gene Polymorphism And Epithelial Ovarian Cancer And The Efficacy Of Platinum-based Drugs

Objective: To analyze the clinical data of epithelial ovarian cancer and to explore the relationship between XRCC1 Gln399 Arg and GSTP1A313 G gene polymorphisms and the efficacy of platinum-based drugs for epithelial ovarian cancer,and provide more powerful evidence for clinical individualized chemotherapy.Methods: The clinical data of patients with epithelial ovarian cancer who were treated with satisfactory surgical treatment and confirmed by postoperative histopathology in the gynecology department of the First Affiliated Hospital of Nanchang University from January to September 2018,2017 were collected.59 patients with inclusion and exclusion criteria were included.The relationship between age,stage,histological type,preoperative serum CA125,XRCC1,GSTP1 and other platinum-related drugs was analyzed.Statistical analysis was performed using SPSS22.0 software using Logistic regression analysis.P<0.05 was considered statistically significant.Results:(1)Multivariate logistic regression analysis showed that there was no significant difference in age,stage,histological type,preoperative CA125 and platinum drug efficacy in patients with epithelial ovarian cancer,P value was greater than 0.05;XRCC1 Gln399 Arg There was significant difference between the gene polymorphism and the efficacy of platinum-based drugs in epithelial ovarian cancer,P<0.05.There was significant difference between the GSTP1 A313 G gene polymorphism and the epithelial ovary on platinum drugs(P<0.05).(2)There was a statistically significant difference in the efficacy of platinum-based drugs between XRCC1 Gln399 Arg mutant homozygous(CC)and wild homozygous(TT)epithelial ovarian cancer(OR=0.032,95% CI: 0.003~0.389).P < 0.05),more sensitive to platinum drugs;there was no significant difference in the efficacy of platinum-based drugs between patients with mutated heterozygous(TC)and wild homozygous(TT)epithelial ovarian cancer,P>0.05.There was a statistically significant difference in the efficacy of GSTP1 A313 G mutant heterozygous(GA)and wild homozygous(AA)epithelial ovarian cancer patients(OR=0.104,95% CI: 0.013~0.845,P<0.05).),more sensitive to platinum drugs.There was a statistically significant difference in the efficacy of GSTP1 A313 G mutant homozygous(GG)and wild homozygous(AA)epithelial ovarian cancer patients(OR=0.041,95% CI: 0.004-0.380,P< 0.05),more sensitive to platinum drugs.(3)Patients with XRCC1 wild homozygous(TT)and GSTP1 wild homozygous(AA)patients with XRCC1 mutation homozygous(CC)and GSTP1 wild homozygous(AA)epithelial ovarian cancer The difference in efficacy between platinum drugs was statistically significant(OR=30.000,95% CI: 1.298-693.132,P<0.05),and platinum drug resistance was more likely to occur.There are statistical differences in the efficacy of platinum-based drugs that carry both wild-type homozygous(TT)and mutant homozygous(GG)and those who carry both mutant homozygous(CC)and wild-type homozygous(AA)epithelial ovarian cancer.The significance of learning(OR = 30.000,95% CI: 1.298 ~ 693.000,P <0.05),more susceptible to platinum drug resistance.There are statistically significant differences in the efficacy of platinum-based drugs that carry both mutant heterozygous(TC)and mutagenic homozygous(GG)and those who carry both mutant homozygous(CC)and wild homozygous(AA)epithelial ovarian cancer.The significance of learning(OR=45.000,95% CI: 2.160~937.321,P<0.05)is more prone to platinum drug resistance.Conclusions:(1)XRCC1 Gln399 Arg and GSTP1 A313 G gene polymorphisms are associated with the efficacy of platinum-based drugs in epithelial ovarian cancer.(2)There may be a certain combined effect between XRCC1 Gln399 Arg and GSTP1 A313 G gene polymorphisms.